<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="186628">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00664209</url>
  </required_header>
  <id_info>
    <org_study_id>MJJF Clinical Discovery 2007</org_study_id>
    <secondary_id>441437-JB-58330</secondary_id>
    <nct_id>NCT00664209</nct_id>
  </id_info>
  <brief_title>Treating H. Pylori in Parkinson's Patients With Motor Fluctuations</brief_title>
  <official_title>Helicobacter Pylori Eradication and Motor Fluctuations in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Michael J. Fox Foundation for Parkinson's Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether treatment of H. pylori (an infection of
      the stomach) improves treatment effectiveness in patients with Parkinson's disease and motor
      fluctuations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous investigations have demonstrated that treatment of Helicobacter pylori with
      antibiotics leads to improved absorption and pharmacokinetics of levodopa. This may
      potentially benefit patients with Parkinson's disease who have motor fluctuations,
      specifically excessive &quot;off&quot; time, when their levodopa is not working to control symptoms.
      We seek to identify the frequency of H. pylori infection in this population using standard
      lab assays and determine whether eradication with standard triple therapy results in
      improved clinical response to medication.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average total daily &quot;off&quot; time (measured by patient symptom diaries)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in UPDRS total scores (&quot;on&quot; and &quot;off&quot;)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in UDPRS Part III (Motor) scores (&quot;on&quot; and &quot;off&quot;)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in quality of life measures (using PDQ-39)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects profile</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Helicobacter Infections</condition>
  <condition>Motor Fluctuations</condition>
  <arm_group>
    <arm_group_label>Active-placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>These subject receive treatment with active triple therapy followed by treatment with placebo therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-active</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>These subject receive treatment with placebo therapy followed by treatment with active triple therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clartihromycin, amoxicillin, and omeprazole</intervention_name>
    <description>clarithromycin 500mg - i PO BID x10 days; amoxicillin 1gm - i PO BID x10 days; omeprazole 10mg - i PO BID x10 days</description>
    <arm_group_label>Active-placebo</arm_group_label>
    <arm_group_label>Placebo-active</arm_group_label>
    <other_name>Biaxin, Prilosec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo therapy</description>
    <arm_group_label>Active-placebo</arm_group_label>
    <arm_group_label>Placebo-active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Adults diagnosed with idiopathic Parkinson's disease, Hoehn &amp; Yahr stage 2-4 in the
             &quot;off&quot; state, with no other concomitant neurologic diseases.

          -  Stable (≥30 days) Parkinson's disease therapy, with demonstrable medication efficacy,
             but with wearing off phenomenon present between levodopa doses (average off time ≥3
             hours off time/day).

          -  Levodopa therapy required; Any formulation (e.g. Sinemet, Sinemet CR, Stalevo) is
             acceptable. Parkinson's disease treatment may also include any of the following
             medications or classes: non-ergot dopamine agonists, COMT inhibitors, MAO-B
             inhibitors, amantadine, anticholinergics.

          -  Positive for H. pylori IgG Ab by serum ELISA (before inclusion in randomized
             treatment arms).

        Exclusion criteria:

          -  Current abdominal pain, unexplained nausea/vomiting, or gastrointestinal bleeding.

          -  History of gastric cancer, peptic ulcer, duodenal ulcer, or other gastric or duodenal
             lesions.

          -  History of previous gastric surgery.

          -  History of previous brain surgery for Parkinson's disease.

          -  Family history of gastric cancer.

          -  Prior treatment for H. pylori+ status.

          -  Recent use (previous 4 weeks) of proton-pump inhibitor, amoxicillin, or
             clarithromycin.

          -  Allergy or sensitivity to penicillin, amoxicillin, clarithromycin, or omeprazole.

          -  Use of drugs affecting gastric motility (e.g. domperidone, metoclopramide).

          -  Inability to tolerate or participate in testing in the morning in an &quot;off&quot; state.

          -  Inability to communicate effectively with study personnel in English.

          -  Pregnancy.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff M Bronstein, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA Neurology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicholas R Szumski, MD</last_name>
    <phone>310-206-4144</phone>
    <email>nszumski@mednet.ucla.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA Neurology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Belhoussine-Idrissi L, Boedeker EC. Helicobacter pylori infection: treatment. Curr Opin Gastroenterol. 2002 Jan;18(1):26-33.</citation>
    <PMID>17031226</PMID>
  </reference>
  <reference>
    <citation>Pierantozzi M, Pietroiusti A, Brusa L, Galati S, Stefani A, Lunardi G, Fedele E, Sancesario G, Bernardi G, Bergamaschi A, Magrini A, Stanzione P, Galante A. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology. 2006 Jun 27;66(12):1824-9.</citation>
    <PMID>16801644</PMID>
  </reference>
  <reference>
    <citation>Pierantozzi M, Pietroiusti A, Galante A, Sancesario G, Lunardi G, Fedele E, Giacomini P, Stanzione P. Helicobacter pylori-induced reduction of acute levodopa absorption in Parkinson's disease patients. Ann Neurol. 2001 Nov;50(5):686-7.</citation>
    <PMID>11706979</PMID>
  </reference>
  <reference>
    <citation>Pierantozzi M, Pietroiusti A, Sancesario G, Lunardi G, Fedele E, Giacomini P, Frasca S, Galante A, Marciani MG, Stanzione P. Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson's disease patients. Neurol Sci. 2001 Feb;22(1):89-91.</citation>
    <PMID>11487216</PMID>
  </reference>
  <reference>
    <citation>Wolle K, Malfertheiner P. Treatment of Helicobacter pylori. Best Pract Res Clin Gastroenterol. 2007;21(2):315-24. Review.</citation>
    <PMID>17382279</PMID>
  </reference>
  <verification_date>April 2008</verification_date>
  <lastchanged_date>April 21, 2008</lastchanged_date>
  <firstreceived_date>April 21, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Jeff Bronstein, MD, PhD</name_title>
    <organization>UCLA Neurology</organization>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>levodopa</keyword>
  <keyword>Helicobacter pylori</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
